FDA Approval for Life-Saving NurOwn for ALS Patients

0 have signed. Let’s get to 75,000!


Amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig's disease, is a specific disease that causes the death of neurons controlling voluntary muscles. Some also use the term motor neuron disease for a group of conditions of which ALS is the most common. ALS is characterized by stiff muscles, muscle twitching, and gradually worsening weakness due to muscles decreasing in size. It may begin with weakness in the arms or legs, or with difficulty speaking or swallowing. About half of the people affected develop at least mild difficulties with thinking and behavior and most people experience pain. Most eventually lose the ability to walk, use their hands, speak, swallow, and breathe. 

ALS does not have to be a death sentence as patients are getting better with BrainStorm Cell Therapeutics stem cell driven therapy NurOwn which aims to help these nerve cells survive by fighting the neurodegeneration process that causes ALS symptoms.

NurOwn uses MSCs harvested from the patient. MSCs are precursor cells that have the ability to differentiate into various cell types. NurOwn’s technology encourages MSCs to develop into cells that secrete neurotrophic factors (NTFs) that promote the growth of nervous tissue. NTFs can also help nerve cells survive through their own neuroprotective function.

Below is a video of the amazing impact that NurOwn is having on ALS patients. Please sign this position to help get full FDA approval for NurOwn. To give people their lives back. Their futures back. Most importantly to give them a fighting chance at HOPE.

 

Please share this petition on your social media and with family, friends, and co-workers. Thank you!

 

Please View Videos Below: Thank you for your time

(LATEST VIDEO UPDATE) https://www.facebook.com/6209609/posts/10107753561682093/

 

https://philadelphia.cbslocal.com/2019/03/11/als-patients-fighting-fda-for-experimental-drug-nurown/

 

https://www.bloomberg.com/news/articles/2019-02-05/right-to-try-law-namesake-gets-als-therapy-says-it-s-working